Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;11(6):688-98.

Conatumumab, a Fully Human mAb Against Death Receptor 5 for the Treatment of Cancer

Affiliations
  • PMID: 20496264
Review

Conatumumab, a Fully Human mAb Against Death Receptor 5 for the Treatment of Cancer

Henry M Rosevear et al. Curr Opin Investig Drugs. .

Abstract

Conatumumab (AMG-655), under development by Amgen Inc and Japanese licensee Takeda Bio Development Center Ltd, is a fully human IgG1 mAb that binds to the extracellular domain of death receptor 5 (DR5) for the potential intravenous treatment of cancer. In vitro and in vivo studies have demonstrated that conatumumab induces apoptosis in cell lines derived from colon and pancreatic cancers, as well as in mice bearing xenograft tumors. Preclinical studies also indicated that conatumumab enhances the antitumor activity of agents, such as irinotecan and gemcitabine. The results of phase I clinical trials have demonstrated the safety of conatumumab as a monotherapy, as well as in combination with other antibody therapies or standard chemotherapeutic regimes. In addition, anti-conatumumab antibody responses have not been observed in the trials conducted to date. At the time of publication, initial results from phase I/II trials suggest a possible therapeutic role for conatumumab in patients with tumors expressing DR5.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

MeSH terms

Substances

LinkOut - more resources

Feedback